|Videos|October 7, 2020
Using the New Indication for Esketamine to Treat Patients with Major Depressive Disorder
Author(s)Gerard Sanacora, MD, PhD
Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.
Advertisement
Dr Sanacora is a Professor of Psychiatry at Yale University, Director of the Yale Depression Research Program, and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Psychiatric Times
1
OCD, Psychedelics, and Cannabinoids: New Evidence
2
Glutamate and GABA: The Yin and Yang of the Human Brain
3
From Practice to Purpose: Cultivating Leadership in Psychiatry
4
Lisdexamfetamine Dimesylate Oral Solution for ADHD to Be Available Mid-2026
5